Next Article in Journal
De Novo Transcriptome Sequencing of Oryza officinalis Wall ex Watt to Identify Disease-Resistance Genes
Next Article in Special Issue
Statin Therapy and the Development of Cerebral Amyloid Angiopathy—A Rodent in Vivo Approach
Previous Article in Journal
miR-29a Participated in Nacre Formation and Immune Response by Targeting Y2R in Pinctada martensii
Previous Article in Special Issue
Aβ1-25-Derived Sphingolipid-Domain Tracer Peptide SBD Interacts with Membrane Ganglioside Clusters via a Coil-Helix-Coil Motif
Article Menu
Issue 12 (December) cover image

Export Article

Open AccessCommunication
Int. J. Mol. Sci. 2015, 16(12), 29446-29453; doi:10.3390/ijms161226181

New Insights to Clathrin and Adaptor Protein 2 for the Design and Development of Therapeutic Strategies

1
Department of Molecular Biology and Genetics, Aarhus University, Gustav Wieds Vej, 10C, Aarhus 8000, Denmark
2
Institute of Biomedicine, Aarhus University, Bartholins Alle’, 6, Aarhus 8000, Denmark
*
Author to whom correspondence should be addressed.
Academic Editor: Amal Kaddoumi
Received: 2 October 2015 / Revised: 18 November 2015 / Accepted: 30 November 2015 / Published: 10 December 2015
(This article belongs to the Special Issue Amyloid-beta and Neurological Diseases)
View Full-Text   |   Download PDF [1559 KB, uploaded 10 December 2015]   |  

Abstract

The Amyloid Precursor Protein (APP) has been extensively studied for its role as the precursor of the β-amyloid protein (Aβ) in Alzheimer’s disease (AD). However, our understanding of the normal function of APP is still patchy. Emerging evidence indicates that a dysfunction in APP trafficking and degradation can be responsible for neuronal deficits and progressive degeneration in humans. We recently reported that the Y682 mutation in the 682YENPTY687 domain of APP affects its binding to specific adaptor proteins and leads to its anomalous trafficking, to defects in the autophagy machinery and to neuronal degeneration. In order to identify adaptors that influence APP function, we performed pull-down experiments followed by quantitative mass spectrometry (MS) on hippocampal tissue extracts of three month-old mice incubated with either the 682YENPTY687 peptide, its mutated form, 682GENPTY687 or its phosphorylated form, 682pYENPTY687. Our experiments resulted in the identification of two proteins involved in APP internalization and trafficking: Clathrin heavy chain (hc) and its Adaptor Protein 2 (AP-2). Overall our results consolidate and refine the importance of Y682 in APP normal functions from an animal model of premature aging and dementia. Additionally, they open the perspective to consider Clathrin hc and AP-2 as potential targets for the design and development of new therapeutic strategies. View Full-Text
Keywords: Clathrin heavy chain; APP; 682YENPTY687; AICD; AP-2; Alzheimer’s disease Clathrin heavy chain; APP; 682YENPTY687; AICD; AP-2; Alzheimer’s disease
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Poulsen, E.T.; Larsen, A.; Zollo, A.; Jørgensen, A.L.; Sanggaard, K.W.; Enghild, J.J.; Matrone, C. New Insights to Clathrin and Adaptor Protein 2 for the Design and Development of Therapeutic Strategies. Int. J. Mol. Sci. 2015, 16, 29446-29453.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top